These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 25525909)

  • 1. Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.
    Hassapis KA; Stylianou DC; Kostrikis LG
    Viruses; 2014 Dec; 6(12):5047-76. PubMed ID: 25525909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of inovirus-associated vector vaccines using phage-display technologies.
    Stern Z; Stylianou DC; Kostrikis LG
    Expert Rev Vaccines; 2019 Sep; 18(9):913-920. PubMed ID: 31373843
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV-1 vaccine strategies utilizing viral vectors including antigen- displayed inoviral vectors.
    Hassapis KA; Kostrikis LG
    Curr HIV Res; 2013 Dec; 11(8):610-22. PubMed ID: 24517188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties].
    Vzorov AN; Compans RW
    Mol Biol (Mosk); 2016; 50(3):406-15. PubMed ID: 27414779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development.
    Samoylova TI; Braden TD; Spencer JA; Bartol FF
    Curr Med Chem; 2017 Nov; 24(35):3907-3920. PubMed ID: 28901276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope-vaccine strategy against HIV-1: today and tomorrow.
    Liu Z; Xiao Y; Chen YH
    Immunobiology; 2003; 208(4):423-8. PubMed ID: 14748515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systems serology for evaluation of HIV vaccine trials.
    Ackerman ME; Barouch DH; Alter G
    Immunol Rev; 2017 Jan; 275(1):262-270. PubMed ID: 28133810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of humoral immunity in host defense against HIV.
    Baum LL
    Curr HIV/AIDS Rep; 2010 Feb; 7(1):11-8. PubMed ID: 20425053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.
    Srivastava IK; Ulmer JB; Barnett SW
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S33-52. PubMed ID: 15285704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
    Paris RM; Kim JH; Robb ML; Michael NL
    Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses.
    Bolhassani A; Kardani K; Vahabpour R; Habibzadeh N; Aghasadeghi MR; Sadat SM; Agi E
    Immunol Lett; 2015 Dec; 168(2):366-73. PubMed ID: 26518142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An effective HIV vaccine: A combination of humoral and cellular immunity?
    Benmira S; Bhattacharya V; Schmid ML
    Curr HIV Res; 2010 Sep; 8(6):441-9. PubMed ID: 20636279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in the Immunogenic Design of HIV-1 Vaccine].
    Zhang X; Wang T; Yu X
    Bing Du Xue Bao; 2016 Jan; 32(1):88-92. PubMed ID: 27295889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.